Our Science
April 06, 2022
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study
Beyond associations with similar factors to those reported on extracorporeal membrane oxygenation (EMCO) for non-COVID-19 severe acute respiratory distress syndrome, 90-day survival among ECMO-assisted patients with COVID-19 was strongly associated with a centre's experience in venovenous ECMO during the previous year.
April 06, 2022
Relevant Biomarkers in Medical Practices: An Analysis of the Needs Addressed by an International Survey
The main objective of this study was to collect responses from an international panel of physicians on their needs for biomarkers and also to convey the improvement in the outcome to be made possible by the potential development of fast diagnostic tests for these biomarkers.
April 06, 2022
Accuracy of Smart Scales on Weight and Body Composition: Observational Study
Smart scales are not accurate for body composition and should not replace DEXA in patient care.
April 06, 2022
COVID-19 pandemic and worldwide organ transplantation: a population-based study
Understanding how different countries and health-care systems responded to COVID-19-related challenges could facilitate improved pandemic preparedness, notably, how to safely maintain transplant programmes, both with immediate and non-immediate life-saving potential, to prevent loss of patient life-years.
April 06, 2022
Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study
Because of its dynamic design, this model can be continuously updated and holds value as a bedside tool that could refine the prognostic judgements of clinicians in everyday practice, hence enhancing precision medicine in the transplant setting.
April 06, 2022
T-bet+CD27+CD21– B cells poised for plasma cell differentiation during antibody-mediated rejection of kidney transplants
This study delineates a pivotal role for CD27+CD21– activated memory B cells in promoting humoral responses and antibody-mediated rejection in organ transplantation and highlights them as important therapeutic targets.
April 05, 2022
Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities
In patients with chronic coronary syndromes, diabetes is independently associated with mortality and cardiovascular events, including heart failure, which is not accounted by demographics, prior medical history, left ventricular ejection fraction, or use of secondary prevention medication. This is observed across multiple geographic regions and ethnicities, despite marked disparities in the prevalence of diabetes.
April 05, 2022
Intracranial Hemorrhage in the TST Trial
Targeting an LDL cholesterol of <70 mg/dL compared with 100±10 mg/dL in patients with atherosclerotic ischemic stroke nonsignificantly increased the risk of ICH. Incident ICHs were not associated with low LDL cholesterol. Uncontrolled hypertension and anticoagulant therapy were associated with ICH which has important clinical implications.
April 05, 2022
One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial
Uncertainty exists on the optimal transfusion strat- egy in patients with anemia and acute myocardial infarction (AMI). Observational studies and 2 small randomized trials examining the effect on clinical out- comes of various transfusion strategies in AMI patients with anemia have yielded conflicting results, emphasizing the need for larger randomized clinical trials.
April 05, 2022
A CD31-Derived Peptide Prevents the Development of Antibody-Mediated Lesions in a Rat Model of Aortic Allograft
These data support a therapeutic potential for molecules able to restore the CD31 signaling to fight antibody-mediated rejection. P8RI, an agonist synthetic peptide targeting CD31, might prevent DSA production and have a beneficial effect in limiting arterial antibody-mediated lesions. CD31 agonists may become therapeutic tools to prevent and treat solid organ transplant arteriosclerosis.
April 05, 2022
Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells
In summary, this report brings to light the presence of gastric GLP-1-positive cells whose density in the mucosa increases after RYGB and VSG surgeries. It highlights a potential role of stomach-derived GLP-1 acting locally and ascribes a role in physiology and metabolism.
April 05, 2022
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology
Coronary risk stratification should be considered as a critical step to decide whether or not to perform CAD screening, and to define therapeutic goals and optimal treatments.
April 05, 2022
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
Tocilizumab may reduce the need for mechanical and noninvasive ventilation or death by day 14 but not mortality by day 28; further studies are necessary to confirm these preliminary results.
November 16, 2021
The emerging field of non–human leukocyte antigen antibodies in transplant medicine and beyond
In this review, we will provide a comprehensive summary of the paradigm-changing concept of immunity to the non-HLA angiotensin II type 1 receptor (AT1R), discovered by Duška Dragun et al., that began from careful bedside clinical observations, to validated detection of anti-AT1R antibodies and lead to clinical intervention.
November 12, 2021
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial
In patients with acute exacerbation of idiopathic pulmonary fibrosis, adding intravenous cyclophosphamide pulses to glucocorticoids increased 3-month mortality. These findings provide evidence against the use of intravenous cyclophosphamide in such patients.